

Espen Thiis-Evensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7195359/publications.pdf>

Version: 2024-02-01

33
papers

1,184
citations

361045

20
h-index

414034

32
g-index

35
all docs

35
docs citations

35
times ranked

1977
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. <i>PLoS ONE</i> , 2010, 5, e13978.	1.1	102
2	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta OncolÅ³gica</i> , 2014, 53, 1284-1297.	0.8	99
3	Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. <i>Neuroendocrinology</i> , 2017, 104, 1-10.	1.2	89
4	The novel colorectal cancer biomarkers <i>CDO1</i> , <i>ZSCAN18</i> and <i>ZNF331</i> are frequently methylated across gastrointestinal cancers. <i>International Journal of Cancer</i> , 2015, 136, 844-853.	2.3	76
5	Patient tolerance of colonoscopy without sedation during screening examination for colorectal polyps. <i>Gastrointestinal Endoscopy</i> , 2000, 52, 606-610.	0.5	70
6	Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. <i>Acta OncolÅ³gica</i> , 2010, 49, 740-756.	0.8	66
7	Small intestinal neuroendocrine tumors: Prognostic factors and survival. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1084-1091.	0.6	65
8	Air and carbon dioxide volumes insufflated during colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 203-206.	0.5	59
9	<p>Fecal microbiota profiles in treatment-na&iuml;ve pediatric inflammatory bowel disease &ndash; associations with disease phenotype, treatment, and outcome</p>. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 37-49.	1.0	58
10	Phospholipase C Isozymes Are Deregulated in Colorectal Cancer â€“ Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. <i>PLoS ONE</i> , 2011, 6, e24419.	1.1	58
11	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. <i>Cancers</i> , 2019, 11, 909.	1.7	56
12	Survival in neuroendocrine neoplasms; A report from a large Norwegian populationâ€based study. <i>International Journal of Cancer</i> , 2018, 142, 1139-1147.	2.3	37
13	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
14	Evaluation of Right Ventricular Dysfunction by Myocardial Strain Echocardiography in Patients with Intestinal Carcinoid Disease. <i>Journal of the American Society of Echocardiography</i> , 2011, 24, 644-650.	1.2	33
15	Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis. <i>Neuroendocrinology</i> , 2010, 92, 168-177.	1.2	32
16	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta OncolÅ³gica</i> , 2021, 60, 931-941.	0.8	32
17	A Tissue-Based Comparative Effectiveness Analysis of Biomarkers for Early Detection of Colorectal Tumors. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e27.	1.3	30
18	Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 734-741.	0.6	27

#	ARTICLE	IF	CITATIONS
19	Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1425-1431.	0.6	26
20	The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. <i>American Journal of Gastroenterology</i> , 2001, 96, 1901-1907.	0.2	21
21	Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 414-419.	0.6	20
22	Treatment of fulminant ulcerative colitis with cyclosporine A. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1310-1314.	0.6	15
23	Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors. <i>Endocrine Connections</i> , 2013, 2, 50-54.	0.8	14
24	Long-term effectiveness of endoscopic screening on incidence and mortality of colorectal cancer: A randomized trial. <i>United European Gastroenterology Journal</i> , 2013, 1, 162-168.	1.6	13
25	Impact of a colonoscopic screening examination for colorectal cancer on later utilization of distal GI endoscopies. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 948-954.	0.5	10
26	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 840-849.	1.2	8
27	Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small-intestinal neuroendocrine tumours. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 188.	1.0	7
28	Lifestyle predictors for inconsistent participation to fecal based colorectal cancer screening. <i>BMC Cancer</i> , 2022, 22, 172.	1.1	7
29	Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. <i>Future Oncology</i> , 2019, 15, 1997-2007.	1.1	6
30	The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2019, 33, 147-152.	1.2	6
31	Association between lifestyle and site-specific advanced colorectal lesions in screening with faecal immunochemical test and sigmoidoscopy. <i>Digestive and Liver Disease</i> , 2021, 53, 353-359.	0.4	3
32	Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. <i>BMC Cancer</i> , 2020, 20, 466.	1.1	2
33	Sunitinib in patients with pancreatic neuroendocrine tumors (panNETs): Exploratory pharmacogenomic analyses.. <i>Journal of Clinical Oncology</i> , 2019, 37, 255-255.	0.8	0